The Hindu |
Bollywood dreams
The Hindu David plays Robert, an artist diagnosed with liver cancer who falls in love with Maya, played by Shahana Goswami. David talks about the movie and his experience. Excerpts from … This is my first visit to India. I’ve a friend who has seen all parts of … |
Immunomedics to Ring Opening Bell and Host R&D Day at the NASDAQ Stock … – Wall Street Journal
|
Immunomedics to Ring Opening Bell and Host R&D Day at the NASDAQ Stock …
Wall Street Journal We have developed a number of advanced proprietary technologies that allow us to create humanized antibodies that can be used either alone in unlabeled or “naked” form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins, … |
Celladon Receives Breakthrough Therapy Designation From FDA for MYDICAR … – GlobeNewswire (press release)
|
Celladon Receives Breakthrough Therapy Designation From FDA for MYDICAR …
GlobeNewswire (press release) SAN DIEGO, April 10, 2014 (GLOBE NEWSWIRE) — Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company developing novel therapies for patients with heart failure and other diseases characterized by SERCA enzyme deficiencies, … Celladon Gets FDA’s “Breakthrough Therapy” Status for Gene TherapyXconomy Celladon Gets Breakthrough Therapy Designation For Mydicar From FDARTT News |
Immunomedics to Ring Opening Bell and Host R&D Day at the NASDAQ Stock … – MarketWatch
|
Immunomedics to Ring Opening Bell and Host R&D Day at the NASDAQ Stock …
MarketWatch We have developed a number of advanced proprietary technologies that allow us to create humanized antibodies that can be used either alone in unlabeled or “naked” form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins, … |
Drug does not improve set of cardiovascular outcomes for diastolic heart failure – National Institutes of Health (press release)
2 Minute MedicineDrug does not improve set of cardiovascular outcomes for diastolic heart failureNational Institutes of Health (press release)A drug that blocks the action of a key hormone did not significantly improve a set of cardiovascular outcomes …
BioLineRx to initiate Phase 1/2 clinical trial on new drug candidate for CML … – News-Medical.net
|
BioLineRx to initiate Phase 1/2 clinical trial on new drug candidate for CML …
News-Medical.net Arnon Nagler, Director of the Hematology Division and Bone Marrow Transplantation Center at Sheba Medical Center, Israel, has received final regulatory approval to evaluate BioLineRx’s BL-8040 as a treatment for chronic myeloid leukemia (CML) in a … |
Ultimate Warrior predicted own death by warning about heart failure – Business Standard
|
Ultimate Warrior predicted own death by warning about heart failure
Business Standard Wrestling champion Ultimate Warrior chillingly predicted his death 20 hour before he actually died by warning about heart failure. The 54-year-old wrestler, born Jim Hellwig, spoke to WWEs flagship show RAW where he said that every man’s heart one day … |
Research and Markets: US Therapeutic Drug Monitoring (TDM) Market 2014 … – Business Wire (press release)
Research and Markets: US Therapeutic Drug Monitoring (TDM) Market 2014 …Business Wire (press release)… Carbamazepine, Cyclosporin, Digoxin, Everolimus, Gentamicin, Levetiracetam, Lithium, Methotrexate, NAPA/Procainamide, Phenobarbital, Phenytoin, Q…
Xencor Receives Milestone Payment from Merck for Initiation of Phase 1 … – PharmiWeb.com (press release)
Xencor Receives Milestone Payment from Merck for Initiation of Phase 1 …PharmiWeb.com (press release)MONROVIA Calif. April 10 2014 /PRNewswire/ — Xencor Inc. (NASDAQ: XNCR) a clinical-stage biopharmaceutical company developing engineered monoclonal …
Xencor Receives Milestone Payment from Merck for Initiation of Phase 1 … – MarketWatch
Xencor Receives Milestone Payment from Merck for Initiation of Phase 1 …MarketWatchMONROVIA, Calif., April 10, 2014 /PRNewswire/ — Xencor, Inc. (NASDAQ:XNCR) , a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies fo…